Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 402

1.

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.

Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J.

Arthritis Res Ther. 2019 Dec 2;21(1):263. doi: 10.1186/s13075-019-2059-8.

2.

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents.

Strand V, Gonçalves J, Hickling TP, Jones HE, Marshall L, Isaacs JD.

BioDrugs. 2019 Nov 13. doi: 10.1007/s40259-019-00394-x. [Epub ahead of print] Review.

PMID:
31721107
3.

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.

Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, Fleischmann R.

RMD Open. 2019 Oct 1;5(2):e001040. doi: 10.1136/rmdopen-2019-001040. eCollection 2019.

4.

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.

Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese MC.

RMD Open. 2019 Oct 18;5(2):e001017. doi: 10.1136/rmdopen-2019-001017. eCollection 2019.

5.

The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study.

Andreasen RA, Kristensen LE, Egstrup K, Baraliakos X, Strand V, Horn HC, Hansen IMJ, Christensen R, Ellingsen T.

Arthritis Res Ther. 2019 Oct 29;21(1):221. doi: 10.1186/s13075-019-2012-x.

6.

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.

Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M.

Qual Life Res. 2019 Oct 26. doi: 10.1007/s11136-019-02296-5. [Epub ahead of print]

PMID:
31655974
7.

Measurement properties of the minimal disease activity criteria for psoriatic arthritis.

Coates LC, Strand V, Wilson H, Revicki D, Stolshek B, Samad A, Chung JB, Gladman D, Mease PJ.

RMD Open. 2019 Sep 6;5(2):e001002. doi: 10.1136/rmdopen-2019-001002. eCollection 2019.

8.

Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data.

Strand V, Shah R, Atzinger C, Zhou J, Clewell J, Ganguli A, Tundia N.

Curr Med Res Opin. 2019 Sep 23:1-8. doi: 10.1080/03007995.2019.1658974. [Epub ahead of print]

PMID:
31433680
9.

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.

Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, Tammara B, Rojo R, Hey-Hadavi J.

RMD Open. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889. eCollection 2019.

10.

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.

Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett W.

J Rheumatol Suppl. 2019 Jun;95:33-37. doi: 10.3899/jrheum.190122.

PMID:
31154402
11.

Reply.

Kim AHJ, Strand V, Atkinson JP.

Arthritis Rheumatol. 2019 Sep;71(9):1590-1592. doi: 10.1002/art.40923. Epub 2019 Jul 19. No abstract available.

PMID:
31074940
12.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.

Klokker L, Berthelsen DB, Woodworth T, Andersen KM, Furst DE, Devoe D, Williamson PR, Suarez-Almazor ME, Strand V, Leong AL, Goel N, Boers M, Brooks PM, March L, Sloan VS, Tugwell P, Simon LS, Christensen R.

J Rheumatol. 2019 Sep;46(9):1173-1178. doi: 10.3899/jrheum.190196. Epub 2019 May 1.

PMID:
31043547
13.

Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort.

Stjarne P, Strand V, Theman K, Ehnhage A.

Rhinology. 2019 Aug 1;57(4):279-286. doi: 10.4193/Rhin18.028.

PMID:
30938376
14.

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.

Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A.

BMC Rheumatol. 2018 Feb 12;2:3. doi: 10.1186/s41927-018-0011-1. eCollection 2018.

15.

Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.

Gossec L, Strand V, Proudfoot C, Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M.

J Rheumatol. 2019 Oct;46(10):1259-1267. doi: 10.3899/jrheum.180904. Epub 2019 Mar 15.

16.

Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis.

Lopez-Olivo MA, Negrón JB, Zogala RJ, Carmona L, Criner K, Goel N, Gonzalez-Lopez L, Ingegnoli F, Leong A, March L, Shea B, Strand V, Tugwell P, Westrich-Robertson T, Zamora NV, Christensen R, Suarez-Almazor ME.

J Rheumatol. 2019 Sep;46(9):1164-1167. doi: 10.3899/jrheum.181076. Epub 2019 Mar 1.

PMID:
30824644
17.

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.

Strand V, McInnes I, Mease P, Nash P, Thom H, Kalyvas C, Hunger M, Gandhi K, Pricop L, Jugl S, Choy E.

J Comp Eff Res. 2019 May;8(7):497-510. doi: 10.2217/cer-2018-0141. Epub 2019 Feb 26.

18.

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.

Strand V, Dimonaco S, Tuckwell K, Klearman M, Collinson N, Stone JH.

Arthritis Res Ther. 2019 Feb 20;21(1):64. doi: 10.1186/s13075-019-1837-7.

19.

Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.

Park EH, Strand V, Oh YJ, Song YW, Lee EB.

Arthritis Res Ther. 2019 Feb 15;21(1):61. doi: 10.1186/s13075-019-1842-x.

20.

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.

Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, de Wit M, Eder L, Fallon L, FitzGerald O, Gladman DD, Goel N, Holland R, Lindsay C, Maxwell L, Mease P, Orbai AM, Shea B, Strand V, Veale DJ, Tillett W, Ogdie A.

J Rheumatol. 2019 Aug;46(8):996-1005. doi: 10.3899/jrheum.181089. Epub 2019 Feb 15.

PMID:
30770518
21.

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.

Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1021-1027. doi: 10.3899/jrheum.181096. Epub 2019 Feb 15.

PMID:
30770515
22.

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.

Maxwell LJ, Beaton DE, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit M, Gossec L, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1014-1020. doi: 10.3899/jrheum.181097. Epub 2019 Feb 15.

PMID:
30770502
23.

Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop.

Morgan EM, Munro JE, Horonjeff J, Horgan B, Shea B, Feldman BM, Clairman H, Bingham CO 3rd, Thornhill S, Strand V, Alongi A, Magni-Manzoni S, van Rossum MAJ, Vesely R, Vojinovic J, Brunner HI, Harris JG, Horton DB, Lovell DJ, Mannion M, Rahimi H, Ravelli A, Ringold S, Ruperto N, Schrandt MS, Shenoi S, Shiff NJ, Toupin-April K, Tzaribachev N, Weiss P, Consolaro A.

J Rheumatol. 2019 Aug;46(8):1006-1013. doi: 10.3899/jrheum.181088. Epub 2019 Feb 15.

PMID:
30770499
24.

Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study.

Alten R, Conaghan PG, Strand V, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Deodhar A.

Clin Rheumatol. 2019 Jun;38(6):1615-1626. doi: 10.1007/s10067-019-04446-z. Epub 2019 Feb 4.

PMID:
30719594
25.

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000808. doi: 10.1136/rmdopen-2018-000808. eCollection 2019.

26.

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000806. doi: 10.1136/rmdopen-2018-000806. eCollection 2019.

27.

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.

Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1028-1035. doi: 10.3899/jrheum.181218. Epub 2019 Feb 1.

PMID:
30709952
28.

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.

van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators.

Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24.

29.

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies.

Bangert E, Wakani L, Merchant M, Strand V, Touma Z.

Patient Relat Outcome Meas. 2019 Jan 9;10:1-7. doi: 10.2147/PROM.S134326. eCollection 2019. Review.

30.

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials.

Andersen KM, Cheah JTL, March L, Bartlett SJ, Beaton D, Bingham CO 3rd, Brooks PM, Christensen R, Conaghan PG, D'Agostino MA, de Wit M, Dueck AC, Goodman SM, Grosskleg S, Hill CL, Howell M, Mackie SL, Richards B, Shea B, Singh JA, Strand V, Tugwell P, Wells GA, Simon LS.

J Rheumatol. 2019 Aug;46(8):1053-1058. doi: 10.3899/jrheum.181123. Epub 2019 Jan 15.

PMID:
30647191
31.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, Veselý R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Sep;46(9):1159-1163. doi: 10.3899/jrheum.181081. Epub 2019 Jan 15.

PMID:
30647174
32.

The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis.

Wechalekar MD, Najm A, Veale DJ, Strand V.

J Rheumatol. 2019 Oct;46(10):1365-1368. doi: 10.3899/jrheum.181062. Epub 2019 Jan 15.

PMID:
30647173
33.

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.

Curtis JR, Flake DD, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS.

Rheumatology (Oxford). 2019 May 1;58(5):874-883. doi: 10.1093/rheumatology/key367.

34.

Correction to: Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Najm A, Le Goff B, Orr C, Thurlings R, Cañete JD, Humby F, Alivernini S, Manzo A, Just SA, Romão VC, Krenn V, Müller-Ladner U, Addimanda O, Tas SW, Stoenoiu M, de Bellefon LM, Durez P, Strand V, Wechalekar MD, Fonseca JE, Lauwerys B, Fearon U, Veale DJ; EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group.

Arthritis Res Ther. 2018 Dec 19;20(1):282. doi: 10.1186/s13075-018-1795-5.

35.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Duffin KC, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2019 Aug;46(8):990-995. doi: 10.3899/jrheum.181077. Epub 2018 Dec 15.

PMID:
30554154
36.

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial.

Strand V, Alemao E, Lehman T, Johnsen A, Banerjee S, Ahmad HA, Mease PJ.

Arthritis Res Ther. 2018 Dec 6;20(1):269. doi: 10.1186/s13075-018-1769-7.

37.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

38.

Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Najm A, Le Goff B, Orr C, Thurlings R, Cañete JD, Humby F, Alivernini S, Manzo A, Just SA, Romão VC, Krenn V, Müller-Ladner U, Addimanda O, Tas SW, Stoenoiu M, Meric de Bellefon L, Durez P, Strand V, Wechalekar MD, Fonseca JE, Lauwerys B, Fearon U, Veale DJ; EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group.

Arthritis Res Ther. 2018 Dec 3;20(1):265. doi: 10.1186/s13075-018-1762-1. Erratum in: Arthritis Res Ther. 2018 Dec 19;20(1):282.

39.

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.

Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, Kalyvas C, Gandhi KK, Porter B, Jugl SM.

Eur J Rheumatol. 2018 Dec;5(4):216-223. doi: 10.5152/eurjrheum.2018.18162. Epub 2018 Oct 30.

40.

Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.

Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S.

Arthritis Care Res (Hoboken). 2019 Jun;71(6):829-838. doi: 10.1002/acr.23788. Epub 2019 Apr 29.

41.

Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.

Kim AHJ, Strand V, Sen DP, Fu Q, Mathis NL, Schmidt MJ, Bruchas RR, Staten NR, Olson PK, Stiening CM, Atkinson JP.

Arthritis Rheumatol. 2019 Mar;71(3):420-430. doi: 10.1002/art.40747. Epub 2019 Jan 24.

42.

Classification and Outcome Measures for Psoriatic Arthritis.

Leung YY, Ogdie A, Orbai AM, Tillett W, Coates LC, Strand V, Mease P, Gladman DD.

Front Med (Lausanne). 2018 Sep 6;5:246. doi: 10.3389/fmed.2018.00246. eCollection 2018. Review.

43.

Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs.

Bodick N, Williamson T, Strand V, Senter B, Kelley S, Boyce R, Lightfoot-Dunn R.

Rheumatol Ther. 2018 Dec;5(2):475-498. doi: 10.1007/s40744-018-0125-3. Epub 2018 Sep 10.

44.

Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.

Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Jugl SM, Gandhi KK; MEASURE 2 study group.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):260-269. Epub 2018 Jul 19.

PMID:
30148436
45.

Functional impairment measurement in psoriatic arthritis: Importance and challenges.

Mease P, Strand V, Gladman D.

Semin Arthritis Rheum. 2018 Dec;48(3):436-448. doi: 10.1016/j.semarthrit.2018.05.010. Epub 2018 May 23. Review.

46.

Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity.

Karpouzas GA, Strand V, Ormseth SR.

RMD Open. 2018 Jun 28;4(1):e000695. doi: 10.1136/rmdopen-2018-000695. eCollection 2018.

47.

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Kivitz AJ, Smolen JS, Burmester GR.

RMD Open. 2018 Jun 17;4(1):e000602. doi: 10.1136/rmdopen-2017-000602. eCollection 2018.

48.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Oct 1;57(10):1777-1788. doi: 10.1093/rheumatology/key161.

49.

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.

Arthritis Res Ther. 2018 Jun 19;20(1):129. doi: 10.1186/s13075-018-1614-z.

50.

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.

McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK; FUTURE 2 Study Group.

Arthritis Res Ther. 2018 Jun 7;20(1):113. doi: 10.1186/s13075-018-1610-3.

Supplemental Content

Loading ...
Support Center